Research graph
References from Evaluating Vaginal Microbiome Effects on Antiretroviral Exposure in the Female Genital Tract Using Pharmacometric and Machine Learning Approaches. Local targets link to admitted publications; unresolved targets remain external evidence.
Advances in HIV treatment and vaccine development: emerging therapies and breakthrough strategies for long‐term control
10.1155/arat/6829446 · 2025 · External reference
Women with HIV: increased need for reproductive health services to improve health outcomes
10.1097/qad.0000000000004096 · 2025 · External reference
Emtricitabine‐tenofovir concentrations and pre‐exposure prophylaxis efficacy in men who have sex with men
10.1126/scitranslmed.3004006 · 2012 · External reference
Preexposure prophylaxis for HIV infection among African women
10.1056/nejmoa1202614 · 2012 · External reference
Tenofovir‐based preexposure prophylaxis for HIV infection among African women
10.1056/nejmoa1402269 · 2015 · External reference
HIV PrEP trials: the road to success
10.4155/cli.12.155 · 2013 · External reference
Hormones, microbes, and PrEP drugs in the female genital tract
10.1080/17425255.2025.2476792 · 2025 · External reference
Vaginal microbiome modulates topical antiretroviral drug pharmacokinetics
10.1172/jci.insight.99545 · 2018 · External reference
Prevotella bivia influences antiretroviral pharmacokinetics and viral replication in an ex vivo vaginal tissue model
10.1111/cts.70597 · 2026 · External reference
Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women
10.1126/science.aai9383 · 2017 · External reference
Experimental design and efficient parameter estimation in population pharmacokinetics
10.1007/bf01062273 · 1990 · External reference
Machine learning and deep learning applications in microbiome research
10.1038/s43705-022-00182-9 · 2022 · External reference
Machine learning approaches in microbiome research: challenges and best practices. Review
10.3389/fmicb.2023.1261889 · 2023 · External reference
Basic concepts in population modeling, simulation, and model‐based drug development‐part 2: introduction to pharmacokinetic modeling methods
10.1038/psp.2013.14 · 2013 · External reference
Depot medroxyprogesterone acetate and the vaginal microbiome as modifiers of Tenofovir diphosphate and lamivudine triphosphate concentrations in the female genital tract of Ugandan women: implications for Tenofovir Disoproxil fumarate/lamivudine in Preexposure prophylaxis
10.1093/cid/ciz443 · 2019 · External reference
Unresolved reference
2017 · External reference
The role of tenofovir alafenamide in future HIV management
10.1111/hiv.12401 · 2016 · External reference
Safety and pharmacokinetics of a Tenofovir Alafenamide fumarate‐Emtricitabine based Oral antiretroviral regimen for prevention of HIV Acquisition in Women: a randomized controlled trial
10.1016/j.eclinm.2021.100893 · 2021 · External reference
A multicompartment population PK model to predict tenofovir and emtricitabine mucosal tissue concentrations for HIV prevention
10.1002/psp4.13042 · 2023 · External reference
Unresolved reference
External reference
Lamivudine/Tenofovir Disoproxil fumarate is an appropriate PrEP regimen
10.1007/s40265-020-01419-4 · 2020 · External reference
Easy and reliable maximum a posteriori Bayesian estimation of pharmacokinetic parameters with the open‐source R package mapbayr
10.1002/psp4.12689 · 2021 · External reference
Efficacy, safety, and effect on sexual behaviour of on‐demand pre‐exposure prophylaxis for HIV in men who have sex with men: an observational cohort study
10.1016/s2352-3018(17)30089-9 · 2017 · External reference
Event‐driven PrEP beyond cisgender men who have sex with men
10.1016/s2352-3018(24)00300-x · 2025 · External reference
A translational pharmacology approach to predicting outcomes of Preexposure prophylaxis against HIV in men and women using Tenofovir Disoproxil fumarate with or without Emtricitabine
10.1093/infdis/jiw077 · 2016 · External reference
Pharmacological evaluation of an ex vivo cervicovaginal HIV prevention model
10.1093/jac/dkag103 · 2026 · External reference
Clinician guide to microbiome testing
10.1007/s10620-018-5299-6 · 2018 · External reference
The power of microbiome studies: some considerations on which alpha and beta metrics to use and how to report results
10.3389/fmicb.2021.796025 · 2022 · External reference
Unresolved reference
2018 · External reference
Compositional data analysis of the microbiome: fundamentals, tools, and challenges
10.1016/j.annepidem.2016.03.002 · 2016 · External reference
Complex heatmap visualization
10.1002/imt2.43 · 2022 · External reference
Moderated estimation of fold change and dispersion for RNA‐seq data with DESeq2
10.1186/s13059-014-0550-8 · 2014 · External reference
Unresolved reference
External reference
NetCoMi: network construction and comparison for microbiome data in R
10.1093/bib/bbaa290 · 2021 · External reference
Inferring correlation networks from genomic survey data
10.1371/journal.pcbi.1002687 · 2012 · External reference
A novel robust network construction and analysis workflow for mining infant microbiota relationships
10.1128/msystems.01570-24 · 2024 · External reference
Pharmacomicrobiomics
10.1002/cpt.70066 · 2025 · External reference
Vaginal microbiota and mucosal pharmacokinetics of Tenofovir in healthy women using a 90‐day Tenofovir/Levonorgestrel vaginal ring
10.3389/fcimb.2022.799501 · 2022 · External reference
Unresolved reference
External reference
Evaluation of the association between the concentrations of key vaginal bacteria and the increased risk of HIV acquisition in African women from five cohorts: a nested case‐control study
10.1016/s1473-3099(18)30058-6 · 2018 · External reference
Efficacy of oral pre‐exposure prophylaxis (PrEP) for HIV among women with abnormal vaginal microbiota: a post‐hoc analysis of the randomised, placebo‐controlled partners PrEP study
10.1016/s2352-3018(17)30110-8 · 2017 · External reference
Genital inflammation is not associated with decreased vaginal Tenofovir concentrations in women taking Oral PrEP
10.1097/qai.0000000000002884 · 2022 · External reference
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of Tenofovir Alafenamide as 10‐day monotherapy in HIV‐1–positive adults
10.1097/qai.0b013e3182965d45 · 2013 · External reference
Single‐dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissues
10.1093/jac/dkx064 · 2017 · External reference
Pharmacokinetics of Tenofovir Alafenamide when Coadministered with other HIV Antiretrovirals
10.1097/qai.0000000000001699 · 2018 · External reference
Pilot pharmacokinetic study of human immunodeficiency virus‐infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir‐ritonavir
10.1128/aac.01064-08 · 2009 · External reference
Assessment of drug‐drug interactions between Tenofovir Disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors Nevirapine and Efavirenz in HIV‐infected patients
10.1097/01.qai.0000191997.70034.80 · 2006 · External reference
Vaginal microbiome of reproductive‐age women
10.1073/pnas.1002611107 · 2011 · External reference
Differences in the composition of vaginal microbial communities found in healthy Caucasian and black women
10.1038/ismej.2007.12 · 2007 · External reference
Optimizing on‐demand Tenofovir Disoproxil fumarate/Emtricitabine dosing in women for HIV prevention
10.1093/infdis/jiaf459 · 2026 · External reference
On‐demand dosing of HIV Preexposure prophylaxis for women: has their time finally come?
10.1093/infdis/jiaf507 · 2026 · External reference
Why has model‐informed precision dosing not yet become common clinical reality? Lessons from the past and a roadmap for the future
10.1002/cpt.659 · 2017 · External reference
A full model estimation approach for covariate effects: inference based on clinical importance and estimation precision
2004 · External reference
An introduction to the full random effects model
10.1002/psp4.12741 · 2022 · External reference
Microbiome‐informed dosing: exploring gut microbial communities impact on mycophenolate enterohepatic circulation and therapeutic target achievement
10.1002/cpt.3740 · 2025 · External reference
Comparative analysis of lower genital tract microbiome between PCOS and healthy women
10.3389/fphys.2020.01108 · 2020 · External reference
